Search Result

Results for "

ALK2 inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AMPK (2) Anaplastic lymphoma kinase (ALK) (4) Apoptosis (1) Autophagy (4) c-Kit (1) Casein Kinase (1) CDK (1) Checkpoint Kinase (Chk) (1) EGFR (1) JAK (2) Organoid (5) Pim (1) RIP kinase (3) TGF-β Receptor (27) Trk Receptor (1)
By Research Areas:	Cancer (25) Inflammation/Immunology (3) Metabolic Disease (2)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-136773

KER047 ALK2-IN-4	TGF-β Receptor	Metabolic Disease
ALK2-IN-4 is a potent *ALK2* inhibitor extracted from patent WO2020086963A1, compound Formula I free base .

HY-136773A

KER047 succinate ALK2-IN-4 succinate	TGF-β Receptor	Metabolic Disease
ALK2-IN-4 succinate is a potent *ALK2* inhibitor extracted from patent WO2020086963A1, compound Formula I free base .

HY-112815

ALK2-IN-2 1 Publications Verification	TGF-β Receptor	Cancer
ALK2-IN-2 is a potent and selective inhibitor of activin receptor-like kinase 2 (ALK2) with an IC₅₀ of 9 nM, and over 700-fold selectivity against ALK3 .

HY-117887

Fidrisertib BLU-782; IPN-60130; ALK2-IN-1	TGF-β Receptor	Cancer
ALK2-IN-1 is a activin receptor-like kinase-2 (ALK2) inhibitor extracted from patent WO2017181117A1, Compound 876, has an IC₅₀ of <10 nM .

HY-19628

OD36	RIP kinase TGF-β Receptor	Inflammation/Immunology
OD36 is a RIPK2 inhibitor with an IC₅₀ of 5.3 nM. OD36 is a macrocyclic inhibitor with potent binding to the *ALK2* kinase ATP pocket. OD36 shows ALK2-directed activity with K_Ds of 37 nM .

HY-148234

M4K2234	Anaplastic lymphoma kinase (ALK)	Cancer
M4K2234 (compound 26b) is an *ALK2* inhibitor. M4K2234 inhibits ALK2 and ALK5 with IC₅₀s of 5 and 2144 nM, respectively. M4K2234 can be used as a chemical probe for ALK1 and ALK2 protein kinases. M4K2234 can be used for the research of cancer .

HY-153246

ALK2-IN-5	Anaplastic lymphoma kinase (ALK)	Cancer
ALK2-IN-5, pyrazolopyrimidine compound, is an *ALK2* inhibitor. ALK2-IN-5 can inhibit ALK2 activity and FGFR activity. ALK2-IN-5 can be used for the research of disorders associated with ALK2 activity and/or FGFR activity, such as cancer .

HY-155939

M4K2163 dihydrochloride	TGF-β Receptor	Cancer
M4K2163 dihydrochloride is a potent, selective, blood-brain barrier (BBB) permeable activin receptor-like kinase-2 (ALK2) inhibitor, with an IC₅₀ of 19 nM. M4K2163 dihydrochloride can be used in the research of diffuse intrinsic pontine glioma (DIPG) .

HY-151273

ALK5-IN-27	TGF-β Receptor	Cancer
ALK5-IN-27 (Compound EX-04) is a potent ALK-5 inhibitor with an IC₅₀ ≤10 nM. ALK5-IN-27 also inhibits *ALK-2* (selectivity ALK2/ALK5 ≤10) .

HY-19628A

OD36 hydrochloride	RIP kinase TGF-β Receptor	Inflammation/Immunology
OD36hydrochloride is a RIPK2 inhibitor with an IC₅₀ of 5.3 nM. OD36 hydrochloride is a macrocyclic inhibitor with potent binding to the *ALK2* kinase ATP pocket. OD36 hydrochloride shows ALK2-directed activity with K_Ds of 37 nM .

HY-151270

ALK5-IN-25	TGF-β Receptor	Cancer
ALK5-IN-25 (compound EX-02) is a potent ALK-5 inhibitor with an IC₅₀ ≤10 nM.ALK5-IN-25 also inhibits *ALK-2* (selectivity ALK2/ALK5≤10). ALK5-IN-25 can be used for the research of cancer .

HY-109179A

Itacnosertib (hydrocholide) TP-0184 (hydrocholide)	JAK TGF-β Receptor	Cancer
Itacnosertib hydrocholide is an inhibitor of JAK2, ACVR1 (ALK2) and ALK5 .

HY-12274

ML347 5+ Cited Publications LDN 193719	TGF-β Receptor	Cancer
ML347 (LDN193719) is a highly selective *ALK1/ALK2* inhibitor. ML347 has IC₅₀ values of 46 and 32 nM against ALK1 and ALK2, respectively, >300-fold selective over ALK3. ML347 block the phosphorylation of Smad1/5 by TGF-β1 .

HY-109179

Itacnosertib TP-0184	JAK TGF-β Receptor	Cancer
Itacnosertib (TP-0184) is both inhibitor to JAK2, ACVR1 (ALK2) and ALK5 as described in WO2014151871 .

HY-16712

LDN-214117 1 Publications Verification	TGF-β Receptor	Cancer
LDN-214117 is an orally active *ALK2* inhibitor with well-tolerated and good brain penetration. LDN-214117 has a high selectivity and low cytotoxicity for ALK2 with an IC₅₀ value of 24 nM. LDN-214117 also is a specific bone morphogenetic proteins (BMPs) signaling inhibitor and has relatively selective inhibition for BMP6 with an IC₅₀ value of 100 nM. LDN-214117 can be used for the research of fibrodysplasia ossificans progressiva (FOP), diffuse intrinsic pontine glioma (DIPG) ^[2]

HY-12273

DMH-1 5+ Cited Publications	Autophagy TGF-β Receptor	Cancer
DMH-1 is a potent and selective BMP inhibitor with IC₅₀s of 27/107.9/<5/47.6 nM for ALK1/ALK2/ALK3/ALK6, respectively.

HY-161377

M4K2306	TGF-β Receptor	Cancer
M4K2306 is a selective inhibitor for activin receptor-like kinase-2 (ALK2) with an IC₅₀ of 7 nM. M4K2306 is blood brain permeable with a brain to plasma ratio of 75.6 .

HY-12273R

DMH-1 (Standard)	Autophagy TGF-β Receptor	Cancer
DMH-1 (Standard) is the analytical standard of DMH-1. DMH-1 is a potent and selective BMP inhibitor with IC₅₀s of 27/107.9/<5/47.6 nM for ALK1/ALK2/ALK3/ALK6, respectively.

HY-161376

M4K2281	TGF-β Receptor	Cancer
M4K2281 is a selecitve inhibitor for activin receptor-like kinase-2 (ALK2) with an IC₅₀ of 2 nM. M4K2281 exhibits a moderate blood brain permeability with a brain to plasma ratio of 3.7 at 4h .

HY-12071A

LDN193189 Tetrahydrochloride 50+ Cited Publications DM-3189 Tetrahydrochloride	Organoid TGF-β Receptor	Cancer
LDN193189 Tetrahydrochloride is a selective BMP type I receptor inhibitor, which efficiently inhibits *ALK2* and ALK3 (IC₅₀=5 nM and 30 nM, respectively), with weaker effects on ALK4, ALK5 and ALK7 (IC₅₀≥500 nM) .

HY-13418

Dorsomorphin dihydrochloride Maximum Cited Publications 504 Publications Verification Compound C dihydrochloride; BML-275 dihydrochloride	Organoid AMPK TGF-β Receptor Autophagy	Cancer
Dorsomorphin (Compound C) dihydrochloride is a potent, selective and ATP-competitive AMPK inhibitor, with a K_i of 109 nM. Dorsomorphin dihydrochloride inhibits BMP pathway by targeting the type I receptors *ALK2, ALK3, and ALK6*. Dorsomorphin dihydrochloride can reverse autophagy activation and anti-inflammatory effect of Urolithin A (HY-100599).

HY-15897

LDN-212854 1 Publications Verification	TGF-β Receptor	Cancer
LDN-212854 is a bone morphogenetic protein (BMP) inhibitor that potently inhibits *ALK2* (IC₅₀: 1.3 nM). LDN-212854 also inhibits ALK1 (IC₅₀: 2.40 nM). LDN-212854 can be used in the research of fibrodysplasia ossificans progressive and cancers, such as hepatocellular carcinoma (HCC) .

HY-19928

Vactosertib 4 Publications Verification EW-7197; TEW-7197	TGF-β Receptor	Cancer
Vactosertib (EW-7197) is a potent, orally active and ATP-competitive activin receptor-like kinase 5 (ALK5) inhibitor with an IC₅₀ of 12.9 nM. Vactosertib also inhibits ALK2 and ALK4 (IC₅₀ of 17.3 nM) at nanomolar concentrations. Vactosertib has potently antimetastatic activity and anticancer effect .

HY-19928A

Vactosertib Hydrochloride 4 Publications Verification EW-7197 Hydrochloride; TEW-7197 Hydrochloride	TGF-β Receptor	Cancer
Vactosertib Hydrochloride (EW-7197 Hydrochloride) is a potent, orally active and ATP-competitive activin receptor-like kinase 5 (ALK5) inhibitor with an IC₅₀ of 12.9 nM. Vactosertib Hydrochloride also inhibits ALK2 and ALK4 (IC₅₀ of 17.3 nM) at nanomolar concentrations. Vactosertib Hydrochloride has potently antimetastatic activity and anticancer effect .

HY-13418A

Dorsomorphin Maximum Cited Publications 504 Publications Verification Compound C; BML-275	Organoid AMPK TGF-β Receptor Autophagy	Cancer
Dorsomorphin (Compound C) is a selective and ATP-competitive AMPK inhibitor (K_i=109 nM in the absence of AMP). Dorsomorphin (BML-275) selectively inhibits BMP type I receptors *ALK2, ALK3, and ALK6. Dorsomorphin can reverse autophagy* activation and anti-inflammatory effect of Urolithin A (HY-100599) .

HY-146694

RIPK2-IN-1	RIP kinase Anaplastic lymphoma kinase (ALK)	Inflammation/Immunology
RIPK2-IN-1 (compound 18f) is a potent RIPK2 inhibitor with an IC₅₀ of 51 nM. RIPK2-IN-1 inhibits *ALK2* with an IC₅₀ of 5 nM. RIPK2-IN-1 has an IC₅₀ of 390 nM on RIPK2/NOD2 in cell assay .

HY-12278

K02288 2 Publications Verification	TGF-β Receptor	Others
K02288 is a potent bone morphogenetic protein (BMP) type I receptor inhibitor with IC₅₀s of 1.8, 1.1, 6.4 nM for ALK1, ALK2 and ALK6, respectively. K02288 shows slightly weaker inhibition against ALK3 and ALK6 with IC₅₀s of of 5-34 nM.

HY-12071

LDN193189 50+ Cited Publications DM-3189	Organoid TGF-β Receptor	Cancer
LDN193189 is a potent selective BMP type I receptor (BMP I) inhibitor. LDN-193189 efficiently inhibits transcriptional activity of the BMP type I receptors *ALK2* and ALK3 with IC₅₀ values of 5 nM and 30 nM, respectively. LDN-193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva .

HY-12071B

LDN-193189 dihydrochloride 50+ Cited Publications DM-3189 dihydrochloride	TGF-β Receptor Organoid	Cancer
LDN-193189 (dihydrochloride) is a potent selective BMP type I receptor (BMP I) inhibitor. LDN-193189 efficiently inhibits transcriptional activity of the BMP type I receptors *ALK2* and ALK3 with IC₅₀ values of 5 nM and 30 nM, respectively. LDN-193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva .

HY-156470

Multi-kinase-IN-6	Trk Receptor Anaplastic lymphoma kinase (ALK) c-Kit EGFR Pim Casein Kinase Checkpoint Kinase (Chk) CDK Apoptosis	Cancer
Multi-kinase-IN-6 (compound 10e) is a multikinase inhibitor that shows good enzyme inhibitory activity against TrkA, *ALK2, c-KIT, EGFR, PIM1, CK2α, CHK1, and CDK2. Multi-kinase-IN-6 reveals antiproliferative activity against MCF7, HCT116 and EKVX with IC₅₀* values of 3.36 μM, 1.40 μM and 3.49 μM, respectively. Multi-kinase-IN-6 shows cell cycle arrest at the G1/S phase and G1 phase in MCF7 and HCT116 cells with good apoptotic effect .

HY-145608

Zilurgisertib INCB-000928; NBU-928	TGF-β Receptor	Cancer
Zilurgisertib (INCB-000928; NBU-928) is a selective *ALK 2* inhibitor for researching diseases such as cancer.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

ALK2 inhibitor

Inhibitors & Agonists